{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:56:52Z","timestamp":1771581412548,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007155","name":"MRC","doi-asserted-by":"publisher","award":["G0701694"],"award-info":[{"award-number":["G0701694"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Framework VI","award":["HEPACIVAC"],"award-info":[{"award-number":["HEPACIVAC"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["2U19AI082630-06"],"award-info":[{"award-number":["2U19AI082630-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection, would significantly reduce the global burden of disease associated with chronic HCV infection. A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime\/boost regimen induced multi-specific, high-magnitude, durable HCV-specific CD4+ and CD8+ T-cell responses in healthy volunteers, and was more immunogenic than a heterologous Ad regimen. We now assess the immunogenicity of this vaccine regimen in HCV infected patients (including patients with a low viral load suppressed with interferon\/ribavirin therapy), determine T-cell cross-reactivity to endogenous virus, and compare immunogenicity with that observed previously in both healthy volunteers and in HCV infected patients vaccinated with the heterologous Ad regimen. Vaccination of HCV infected patients with ChAd3-NSmut\/MVA-NSmut was well tolerated. Vaccine-induced HCV-specific T-cell responses were detected in 8\/12 patients; however, CD4+ T-cell responses were rarely detected, and the overall magnitude of HCV-specific T-cell responses was markedly reduced when compared to vaccinated healthy volunteers. Furthermore, HCV-specific cells had a distinct partially-functional phenotype (lower expression of activation markers, granzyme B, and TNF\u03b1 production, weaker in vitro proliferation, and higher Tim3 expression, with comparable Tbet and Eomes expression) compared to healthy volunteers. Robust anti-vector T-cells and antibodies were induced, showing that there is no global defect in immunity. The level of viremia at the time of vaccination did not correlate with the magnitude of the vaccine-induced T-cell response. Full-length, next-generation sequencing of the circulating virus demonstrated that T-cells were only induced by vaccination when there was a sequence mismatch between the autologous virus and the vaccine immunogen. However, these T-cells were not cross-reactive with the endogenous viral variant epitopes. Conversely, when there was complete homology between the immunogen and circulating virus at a given epitope T-cells were not induced. T-cell induction following vaccination had no significant impact on HCV viral load. In vitro T-cell culture experiments identified the presence of T-cells at baseline that could be expanded by vaccination; thus, HCV-specific T-cells may have been expanded from pre-existing low-level memory T-cell populations that had been exposed to HCV antigens during natural infection, explaining the partial T-cell dysfunction. In conclusion, vaccination with ChAd3-NSmut and MVA-NSmut prime\/boost, a potent vaccine regimen previously optimized in healthy volunteers was unable to reconstitute HCV-specific T-cell immunity in HCV infected patients. This highlights the major challenge of overcoming T-cell exhaustion in the context of persistent antigen exposure.<\/jats:p>","DOI":"10.3390\/vaccines4030027","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T03:47:39Z","timestamp":1470196059000},"page":"27","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-6715","authenticated-orcid":false,"given":"Leo","family":"Swadling","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Halliday","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"},{"name":"Oxford NIHR BRC, and Translational Gastroenterology Unit, Oxford OX3 9DU, UK"},{"name":"Royal Melbourne Hospital, Parkville, Victoria 3050, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christabel","family":"Kelly","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"},{"name":"Oxford NIHR BRC, and Translational Gastroenterology Unit, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Capone","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ansari","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3479","authenticated-orcid":false,"given":"Rachel","family":"Richardson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicity","family":"Hartnell","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Collier","sequence":"additional","affiliation":[{"name":"Oxford NIHR BRC, and Translational Gastroenterology Unit, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ammendola","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"Del Sorbo","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Von Delft","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Traboni","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Hill","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"},{"name":"The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"},{"name":"CEINGE, via Gaetano Salvatore 486, Naples 80145, Italy"},{"name":"Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, Naples 80131, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cortese","sequence":"additional","affiliation":[{"name":"Keires AG, B\u00e4umleingasse 18, Basel CH 4051, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"},{"name":"Oxford NIHR BRC, and Translational Gastroenterology Unit, Oxford OX3 9DU, UK"},{"name":"The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Folgori","sequence":"additional","affiliation":[{"name":"Reithera Srl (former Okairos Srl), Viale Citt\u00e0 d\u2019Europa, 679, Rome 00144, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK"},{"name":"Oxford NIHR BRC, and Translational Gastroenterology Unit, Oxford OX3 9DU, UK"},{"name":"The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: A systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2015.06.010","article-title":"Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection?","volume":"35","author":"Walker","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","article-title":"HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact","volume":"22","author":"Martin","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dutta, A., Barker, C., and Kallarakal, A. (2015). The HIV treatment gap: Estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001907"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/cit301","article-title":"Hepatitis C virus reinfection following treatment among people who use drugs","volume":"57","author":"Grady","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","article-title":"Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins","volume":"139","author":"Dahari","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2008.03.525","article-title":"Immune responses during acute and chronic infection with hepatitis C virus","volume":"128","author":"Ishii","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence","volume":"119","author":"Rehermann","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gutjnl-2011-300620","article-title":"T cell responses in hepatitis C: The good, the bad and the unconventional","volume":"61","author":"Klenerman","year":"2012","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14712598.2013.791277","article-title":"Ever closer to a prophylactic vaccine for HCV","volume":"13","author":"Swadling","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: Closing in on an evasive target","volume":"10","author":"Halliday","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2012.02.070","article-title":"Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination","volume":"30","author":"Klade","year":"2012","journal-title":"Vaccine"},{"key":"ref_18","first-page":"456","article-title":"GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection","volume":"11","author":"Habersetzer","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","article-title":"Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial","volume":"16","author":"Shoukry","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","article-title":"Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection","volume":"147","author":"Habersetzer","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","article-title":"A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., and Townsend, R. (2012). Novel adenovirus-based vaccines induce broad and sustained T-cell responses to HCV in man. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3003155"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans","volume":"63","author":"Kelly","year":"2015","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Swadling, L., Capone, S., Antrobus, R.D., Brown, A., Richardson, R., Newell, E.W., Halliday, J., Kelly, C., Bowen, D., and Fergusson, J. (2014). A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T-cell memory. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3009185"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1128\/JVI.79.14.8960-8968.2005","article-title":"Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination","volume":"79","author":"Wherry","year":"2005","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni1241","article-title":"T cells and viral persistence: Lessons from diverse infections","volume":"6","author":"Klenerman","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1016\/j.vaccine.2011.03.083","article-title":"A human Phase I\/IIa malaria challenge trial of a polyprotein malaria vaccine","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., and Esposito, M.L. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3002925"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Batty, E.M., Wong, T.H.N., Trebes, A., Argoud, K., Attar, M., Buck, D., Ip, C.L.C., Golubchik, T., Cule, M., and Bowden, R. (2013). A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples. PLoS ONE.","DOI":"10.1371\/journal.pone.0066129"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lamble, S., Batty, E., Attar, M., Buck, D., Bowden, R., Lunter, G., Crook, D., El-Fahmawi, B., and Piazza, P. (2013). Improved workflows for high throughput library preparation using the transposome-based Nextera system. BMC Biotechnol.","DOI":"10.1186\/1472-6750-13-104"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/bioinformatics\/btu781","article-title":"QuasR: Quantification and annotation of short reads in R","volume":"31","author":"Gaidatzis","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J.","DOI":"10.14806\/ej.17.1.200"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yang, X., Charlebois, P., Gnerre, S., Coole, M.G., Lennon, N.J., Levin, J.Z., Qu, J., Ryan, E.M., Zody, M.C., and Henn, M.R. (2012). De novo assembly of highly diverse viral populations. BMC Genom.","DOI":"10.1186\/1471-2164-13-475"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lee, W.P., Stromberg, M.P., Ward, A., Stewart, C., Garrison, E.P., and Marth, G.T. (2014). MOSAIK: A hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS ONE.","DOI":"10.1371\/journal.pone.0090581"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Yang, X., Charlebois, P., Macalalad, A., Henn, M.R., and Zody, M.C. (2013). V-Phaser 2: Variant inference for viral populations. BMC Genom.","DOI":"10.1186\/1471-2164-14-674"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Henn, M.R., Boutwell, C.L., Charlebois, P., Lennon, N.J., Power, K.A., Macalalad, A.R., Berlin, A.M., Malboeuf, C.M., Ryan, E.M., and Gnerre, S. (2012). Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog.","DOI":"10.1371\/journal.ppat.1002529"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Bett","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1099\/vir.0.79801-0","article-title":"Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs","volume":"85","author":"Hakamada","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Guo, Z., Zhang, H., Rao, H., Jiang, D., Cong, X., Feng, B., Wang, J., Wei, L., and Chen, H. (2012). DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS ONE.","DOI":"10.1371\/annotation\/2ea71143-c033-43ff-8282-781b76c0a054"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/597072","article-title":"Cellular Immune Responses during High-Dose Interferon-\u03b1 Induction Therapy for Hepatitis C Virus Infection","volume":"199","author":"Barnes","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1128\/JVI.00995-07","article-title":"Viral sequence evolution in acute hepatitis C virus infection","volume":"81","author":"Kuntzen","year":"2007","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20041006","article-title":"CD8 epitope escape and reversion in acute HCV infection","volume":"200","author":"Timm","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bengsch, B., Seigel, B., Ruhl, M., Timm, J., Kuntz, M., Blum, H.E., Pircher, H., and Thimme, R. (2010). Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T-cells is linked to antigen recognition and T-cell differentiation. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000947"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.celrep.2015.10.034","article-title":"Adenoviral vector vaccination induces a conserved program of CD8(+) T-cell memory differentiation in mouse and man","volume":"13","author":"Bolinger","year":"2015","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alanio, C., Nicoli, F., Sultanik, P., Flecken, T., Perot, B., Duffy, D., Bianchi, E., Lim, A., Clave, E., and van Buuren, M.M. (2015). Bystander hyperactivation of preimmune CD8(+) T-cells in chronic HCV patients. Elife.","DOI":"10.7554\/eLife.07916.037"},{"key":"ref_51","unstructured":"Swadling, L. (2016). Unpublished data."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Callendret, B., Eccleston, H.B., Satterfield, W., Capone, S., Folgori, A., Cortese, R., Nicosia, A., and Walker, C.M. (2015). Persistent HCV replication despite priming of functional CD8+ T-cells by combined therapy with a vaccine and direct acting antiviral. Hepatology.","DOI":"10.1002\/hep.28309"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1586\/erv.11.9","article-title":"IFN-\u03b1 as a vaccine adjuvant: Recent insights into the mechanisms and perspectives for its clinical use","volume":"10","author":"Rizza","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.21541","article-title":"Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection","volume":"45","author":"Penna","year":"2007","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8(+) T-cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2009.10.010","article-title":"The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and eomesodermin","volume":"32","author":"Rao","year":"2010","journal-title":"Immunity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.4049\/jimmunol.1002042","article-title":"Cutting edge: The transcription factor eomesodermin enables CD8+ T-cells to compete for the memory cell niche","volume":"185","author":"Banerjee","year":"2010","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T-cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1084\/jem.20131333","article-title":"Dysfunctional CD8+ T-cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction","volume":"211","author":"Kurktschiev","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/hep.23319","article-title":"Selection-driven immune escape is not a significant factor in the failure of CD4 T-cell responses in persistent hepatitis C virus infection","volume":"51","author":"Fuller","year":"2010","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.21319","article-title":"CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus","volume":"44","author":"Puig","year":"2006","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kanagavelu, S., Termini, J.M., Gupta, S., Raffa, F.N., Fuller, K.A., Rivas, Y., Philip, S., Kornbluth, R.S., and Stone, G.W. (2014). HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T-cell mediated anti-viral immunity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090100"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2015.06.087","article-title":"An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression","volume":"34","author":"Ragonnaud","year":"2016","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K.R., Chang, K.M., Sulkowski, M., Marro, S.O., and Anderson, J. (2013). A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063818"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","article-title":"Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization","volume":"134","author":"Nakamoto","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4049\/jimmunol.1403237","article-title":"CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells","volume":"195","author":"Provine","year":"2015","journal-title":"J. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/4\/3\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:35Z","timestamp":1760210855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/4\/3\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9]]}},"alternative-id":["vaccines4030027"],"URL":"https:\/\/doi.org\/10.3390\/vaccines4030027","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}